The Coalition for Epidemic Preparedness Innovations (CEPI) is a global, non-profit partnership established in 2017 to accelerate the development of vaccines and other biological countermeasures against emerging infectious diseases and pandemic threats. Headquartered in Oslo, Norway, CEPI brings together governments, industry, academia, philanthropic organizations, and multilateral bodies to reduce the time and risk of vaccine development.
CEPI funds and coordinates R&D for priority pathogens such as Lassa fever, Nipah, MERS, Rift Valley fever, and Chikungunya, and advances platform technologies to enable rapid responses to “Disease X.” It works to expand manufacturing capacity and to ensure equitable, affordable access to vaccines worldwide, including for low- and middle-income countries. CEPI co-led the COVAX initiative alongside Gavi and WHO during the COVID-19 pandemic and continues to drive the goal of developing safe, effective vaccines within 100 days of the identification of a novel threat.